患有髓寡腺细胞糖蛋白抗体相关疾病的患者的认知功能
Rebekka Rust1,2,3, Susanna Asseyer4,5,6, Patrick Schindler4,5,6
1Experimental and Clinical Research Center (ECRC), Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. rebekka.rust@charite.de.
Journal of neurology
|January 6, 2026
概括
认知障碍在患有髓寡腺细胞糖蛋白抗体相关疾病 (pwMOGAD) 的患者中很常见. 在pwMOGAD中认知障碍的风险与其他神经髓炎光学谱系障碍中观察到的风险相似.
科学领域:
- 神经免疫学 神经免疫学
- 神经心理学 神经心理学
- 临床神经学 临床神经学
背景情况:
- 成年髓寡细胞糖蛋白抗体相关疾病 (MOGAD) 的认知缺陷尚未得到充分证实.
- 了解MOGAD的认知功能对于患者的护理和管理至关重要.
研究的目的:
- 为了研究MOGAD成年患者的认知功能.
- 将MOGAD患者的认知障碍 (CImp) 风险与健康对照 (HC) 的风险进行比较.
- 为了评估MOGAD中CImp的相对风险 (RR),与水素4-免疫球蛋白G阳性NMOSD (AQP4+NMOSD) 和双阴性NMOSD (dsNMOSD) 患者相比.
主要方法:
- 认知表现使用罗的简短可重复的神经心理测试进行了评估.
- 使用混调整的线性回归来比较MOGAD患者和HC患者.
- 认知障碍 (CImp) 被定义为HC平均值以下两标准偏差的表现;使用通用线性模型计算相对风险 (RR).
主要成果:
- 与HC相比,PwMOGAD在选择性提醒测试和符号数字模式测试中表现较差.
- 在pwMOGAD中,CImp的调整后RR为1.9 (95%CI为0.9-4.1).
- 在 pwAQP4+NMOSD (1.9;95% CI 1.0-3.9) 和 pwdsNMOSD (2.1;95% CI 0.9-4.6) 中观察到类似的Cimp调整后的RR.
结论:
- 与HC相比,PwMOGAD在信息处理速度,口头学习,存储和检索方面表现出缺陷.
- 在pwMOGAD中,认知障碍的相对风险与pwAQP4+NMOSD和pwdsNMOSD中观察到的相似.
- 这些发现凸显了MOGAD对认知影响的重大影响,以及其与其他NMOSD谱系障碍的相似性.
相关概念视频
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Myasthenia Gravis: Diagnostic Tests
1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K


